



DOX-PD-L1-FD1080@LNP

Cat. No. R-Z-DPF-1

Lot. No. (See product label)

Alias	Doxorubicin-PD-L1-FD1080@LNP
Appearance	Dispersion
Molecular Formula	N/A
Solubility	Dispersed in aqueous medium
Storage	-20°C, protected from light
Purity	95%+
Shelf Life	1 year
Shipping Condition	low temperature transport
Application	drug research and development
Specification	10mg : Inquiry 20mg : Inquiry 50mg : Inquiry
Description	DOX/PD-L1/FD1080@LNP is a multifunctional lipid nanoparticle drug delivery system. As a carrier, lipid nanoparticles (LNP) have good biocompatibility, adjustable particle size and surface properties, and can effectively protect the drug molecules wrapped in them to avoid premature degradation or elimination in the body. Doxorubicin (DOX) exerts harmful effects on cells by intercalating into DNA double strands and interfering with DNA replication and transcription. PD-L1 inhibitors can block the combination of PD-L1 and PD-1, activate the body's immunity system, and enhance the ability of immune cells to clear tumor cells. Although the specific substance of FD1080 is not specified,

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY

www.matexcel.com

Address: SUITE 210, 17 Ramsey Road, Shirley, NY 11967

Email: info@matexcel.com Tel: 1-631-869-4956 Fax: 1-631-910-2166



it may be an auxiliary treatment drug or a molecule with special functions. The three are co-loaded in LNP, which can achieve tumor-targeted delivery and use PD-L1 inhibitors to activate the immunity response, while FD1080 works synergistically.

Supplier

Xi'an Ruixi

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY

www.matexcel.com

Address: SUITE 210, 17 Ramsey Road, Shirley, NY 11967

Email: info@matexcel.com Tel: 1-631-869-4956 Fax: 1-631-910-2166